The p53 tumor suppressor protein has a key role in the induction of apoptosis of chronic lymphocytic leukemia (CLL) cells. Abnormalities within the p53 pathway identify a subset of patients with a poor prognosis. This review describes recent advances in understanding the mechanisms that regulate p53 levels and the role of p53 in the control of the cell cycle and of apoptosis. The classical model of p53-mediated apoptosis emphasizes the transcriptional activation of proapoptotic genes. In contrast, a novel model emphasizes p53's non-transcriptional actions as the major route of apoptosis induction, whereas its transcriptional arm predominantly upregulates antiapoptotic genes, thus providing a negative feedback mechanism that limits apoptosis. Further studies have identified the Notch pathway as a candidate p53-induced antiapoptotic mechanism. In contrast to the classical model, the novel model predicts that pharmacological inhibition of p53's transcriptional function or of the Notch signaling pathway will augment apoptosis induction by cytotoxic agents. Therapeutic strategies based on the novel model, which we review here for the first time, may significantly augment the antitumor actions of cytotoxic agents in CLL and in other malignancies.
Introduction
p53 is a well-known tumor suppressor gene, and mutational inactivation of p53 function or deletion of the gene increases susceptibility to cancer. [1] [2] [3] [4] Genetic aberrations that result in functional loss of p53, or which perturb upstream pathways that regulate p53 levels, are a feature of more than half of human malignancies.
The classical model of p53's cellular functions emphasizes its role as a transcription factor. p53 protein levels are upregulated by a post-transcriptional mechanism in response to a range of cellular stresses including DNA damage. p53 then upregulates transcription of genes whose products block the cell cycle at the G 1 /S phase boundary, thereby allowing repair of DNA lesions before DNA replication. 3 Therefore, p53 induction prevents the perpetuation of potentially harmful mutations. However, if DNA damage is extensive, p53-induced transcription of proapoptotic genes results in cell killing, thereby eliminating the damaged cell.
5 p53 is therefore recognized as a major guardian of genomic integrity. 1 In contrast, more recent studies have identified an additional non-transcriptional mechanism by which p53 induces apoptosis. This mechanism is dependent on direct biochemical interactions between p53 and the core apoptotic machinery located on the mitochondrial outer membrane. 6, 7 This review summarizes the basic mechanisms of p53 upregulation and function as well as the evidence of the importance of p53 gene aberrations in the pathobiology of chronic lymphocytic leukemia (CLL). We also present recent data that support a novel model of p53 function in CLL cells, which involves both the transcriptional and non-transcriptional roles of this multifaceted protein. This model also encompasses a key interaction between the p53 and Notch signaling pathways. In complete contrast to the predictions of the classical model, the novel model suggests that inhibition of p53's transcriptional function may in fact enhance apoptosis induction. This model may therefore be of value in designing new therapeutic strategies for the treatment of CLL and of other malignancies.
Cellular regulation of the p53 and Notch pathways
Mechanisms of p53 regulation p53 protein levels are regulated by a complex array of posttranslational modifications. A major mechanism involves the physical interaction between p53 and its negative regulator, Mdm2. Mdm2 is an E3 ubiquitin ligase that continuously conjugates ubiquitin molecules to lysine residues of p53 ( Figure 1 , arrow 1), thereby targeting p53 for proteasomal degradation (arrow 2), and thus maintaining low constitutive p53 levels. 2 Induction of DNA damage results in the activation of protein kinases, including ATM, ATR, Chk1, Chk2 and DNAdependent protein kinase, which phosphorylate serine residues in the N-terminal domain of p53 (arrow 3). These phosphorylation events abolish the p53/Mdm2 interaction and ubiquitination-dependent degradation of p53, with a consequent increase in p53 levels, and its translocation to the nucleus (arrow 4) where it triggers the transcription of p53 target genes (arrow 5). The Mdm2 gene is itself a transcriptional target of p53, resulting in a negative feedback regulatory loop. Recent studies have revealed that post-translational modifications other than phosphorylation (for example, acetylation) can also block the p53/ Mdm2 interaction, thereby contributing additional mechanisms of p53 induction. 2 Upregulated expression of the ARF gene in response to cellular stress resulting from oncogene activation is an alternative mechanism for upregulation of p53. The Arf protein directly blocks the p53/Mdm2 interaction, resulting in p53 stabilization. 8 The phosphatidylinositol 3-kinase/Akt pathway blocks apoptosis by multiple mechanisms including the suppression of the p53 pathway. Phosphorylation of Mdm2 by the serine/ threonine protein kinase Akt enhances Mdm2's ability to ubiquitinate and promote the degradation of p53. 9, 10 This mechanism may be dependent on the promotion of nuclear localization of Mdm2 following its phosphorylation, thus promoting the interaction of Mdm2 with nuclear-localized p53. 9 In contrast, a separate study showed that Mdm2 phosphorylation augmented its intrinsic ability to ubiquitinate p53 without modifying Mdm2's subcellular localization. 10 
Transcriptional targets of p53
p53 upregulates a large number of target genes with diverse functions. 5 Binding of p53 to a consensus DNA sequence in the promoter region of target genes initiates the assembly of multiprotein transcriptional complexes, resulting in gene expression (Figure 1 ). Fine-tuning of the decision as to which genes are expressed in a given context is dependent on a complex set of post-translational modifications, which include methylation, acetylation, sumoylation and neddylation of p53. 2, 3 The pattern of post-translational modifications occurring in a given cell therefore determines the range of target genes expressed, and is defined both by cell type and inducing stimulus. The resulting pattern of gene expression determines whether a given cell will commit to apoptosis, undergo growth arrest or indeed be protected from death (see below).
Well-established targets of p53 include genes encoding the p21 CIP1 , Puma and Noxa proteins. 3-5 p21 CIP1 is induced by low levels of p53 and imposes a blockade on the cell cycle at the G 1 /S phase checkpoint. This blockade is imposed via inhibition of the cyclin E-cyclin-dependent protein kinase 2 complex, thereby allowing repair of DNA lesions before initiation of DNA replication. 5 Puma and Noxa are proapoptotic BH3-only members of the Bcl-2 protein family, which promote apoptosis of cells that have sustained high and consequently irreparable levels of DNA damage. 11 Both the cell cycle blockade coupled with DNA repair and the apoptosis of irreparably damaged cells prevent the perpetuation of potentially harmful mutations and contribute to p53's role as a guardian of genomic integrity.
The tumor suppressor function of p53 has traditionally been interpreted on the basis of its ability to negatively regulate the cell cycle and to induce apoptosis, both of which processes act to limit cell numbers. [1] [2] [3] [4] [5] However, recent studies have revealed a much broader range of cellular responses regulated by p53. These functions include the induction of senescence, autophagy and the repair of DNA lesions. Strikingly, p53 is able, in some cellular contexts, to induce cytoprotective responses. 12 Cytoprotective mechanisms include the induction of Tigar, a protein that diverts glucose metabolism away from glycolysis and toward the pentose phosphate shunt, thereby resulting in nicotinamide adenine dinucleotide phosphate generation. 13 The resultant increase in nicotinamide adenine dinucleotide phosphate and of glutathione provides a potent mechanism for scavenging of toxic reactive oxygen species. Upregulation of the sestrin proteins also augment scavenging of reactive oxygen species. 14 The range of known antiapoptotic targets of p53 have been extensively reviewed elsewhere. 15 Non-transcriptional mechanisms of apoptosis induction by p53
The majority of studies on p53 have focussed on its role as a transcription factor (Figure 1 ). In contrast, recent studies have identified a transcription-independent mechanism for apoptosis induction by p53. 5, 6 p53 mutants that were unable to transactivate proapoptotic target genes were nevertheless able to induce apoptosis in HeLa cells. 16 In vitro assays showed that p53 activated the proapoptotic 'executioner' proteins Bax 17 and Bak 18 at the mitochondrial outer membrane, resulting in cell death induction that was independent of transcription. Activation of Bax and Bak consequent to p53 localization to mitochondria resulted in the release of cytochrome c from these organelles, a key event that results in activation of the apoptotic caspase proteases, resulting in the final execution stage of cell death. 19 However, cooperation between p53's transcriptional and non-transcriptional roles may be required for apoptosis induction in some cellular contexts. Following DNA damage, the induced p53 is sequestered by Bcl-X L , and induction of apoptosis requires displacement of the sequestered p53 by Puma. Puma induction requires the transcriptional arm of p53 function. 20 p53 can be targeted to mitochondria by linkage at its carboxyl terminus to the Bcl-2 or Bcl-X L transmembrane domains, which serve to anchor proteins in the mitochondrial outer membrane. When expressed in cells via a retroviral vector, these constructs locate exclusively to mitochondria and are excluded from the nucleus. 21 Mitochondrially targeted p53 induced efficient apoptosis of lymphoma cells induced in mice by ectopic expression of the MYC oncogene. 21 Therefore, the transcription-independent functions of p53 contribute to its tumor suppressor role. As normal cells are resistant to transfection by the retrovirus, viral transduction of mitochondrially targeted p53 may provide a novel therapeutic option for some malignancies.
Some p53 variants with mutations in the DNA-binding domain are unable to bind Bcl-2 or Bcl-X L , suggesting that this domain of p53 mediates binding to antiapoptotic Bcl-2-family proteins. 22 This conclusion was elegantly confirmed by a nuclear magnetic resonance study, which showed that the p53/Bcl-X L interaction involved the DNA-binding domain of p53 and the Bcl-2 homology 4 (BH4) domain of Bcl-X L . 23 An important consequence of this model is that mutations within the DNA-binding domain that compromise transactivation will concomitantly eliminate transcription-independent apoptosis induction by p53.
In summary, the transcription-independent mechanism of p53-induced apoptosis is likely to be dependent on neutralization of the antiapoptotic functions of Bcl-2, Bcl-X L and possibly p53 and Notch in chronic lymphocytic leukemia RG Wickremasinghe et al of other related proteins consequent to p53 binding. Neutralization of these proteins would then result in the activation of proapoptotic Bax and Bak, the release of cytochrome c from mitochondria, caspase activation and apoptosis. 24 The Notch signaling pathway Recent evidence suggests that the Notch signaling pathway is a downstream target of p53. 25 The p53/Notch interaction may account for some recent observations in CLL cells, 26, 27 which are described in detail below. We therefore review briefly the molecular regulation of the Notch pathway. Notch 1, 2, 3 and 4 constitute a family of heterodimeric transmembrane proteins. Notch ligands belong to the serrate/ jagged and delta families. The extracellular domain of Notch is engaged by ligands usually expressed on the surface of other cells (Figure 2, arrow 1) , resulting in an initial site-specific metalloproteinase-catalyzed proteolytic cleavage in the extracellular domain. This cleavage generates a truncated membrane-bound molecule, Notch extracellular truncation (arrow 2). Intramembrane proteolysis of Notch extracellular truncation by g-secretase releases the Notch intracellular domain (arrow 3), which translocates to the nucleus (arrow 4), resulting in assembly of active transcription complexes by its association with nuclear-localized transcriptional coactivators including CBF1 (arrow 5). 28 Downstream antiapoptotic mechanisms activated by the Notch signaling include the nuclear factor-kB (NF-kB) pathway, 29 which positively regulates expression of antiapoptotic proteins, including cellular inhibitors of apoptotic proteases 1 and 2, X-linked cellular inhibitors of apoptotic protease, Bfl1 and Bcl-X L . 30 Upregulation of the cell cycle-regulating c-MYC transcription factor also mediates leukemic cell expansion in response to Notch activation. 31 Notch signaling also activates Akt, 32 a key protein kinase whose downstream targets are potent blockers of apoptosis. 33 Akt activation is dependent on the suppression of Pten expression by Notch signaling. Pten is a negative regulator of phosphatidylinositol 3-kinase, the upstream activator of Akt. Pten suppression by Notch therefore results in activation of the pathway. 32 The p53 and Notch pathways in CLL
The impact of p53 and ATM mutations and deletions on the pathobiology of CLL Mutations of the genes encoding p53 (refs 34, 15) or its upstream regulator Atm [36] [37] [38] occur in CLL. Deletions of chromosomes 17p or 11q, the locations of the p53 and ATM genes respectively, identify particularly aggressive forms of the malignancy. 39, 40 These deletions are frequently, but not invariably, associated with mutational inactivation of the respective remaining allele, resulting in comprehensive loss of p53-dependent apoptotic responses to DNA-damaging agents. 41, 42 A detailed microarray analysis revealed subtle differences in the transcriptional response to DNA damage between CLL cells with lesions in the p53 or ATM genes. Although all of the proapoptotic responses downstream of Atm activation were dependent on p53, Atm additionally upregulated p53-independent prosurvival responses. 43 These prosurvival responses were blocked by p53, suggesting that the more drastic consequences of p53 loss compared with Atm loss resulted from the additive effects of the loss of proapoptotic gene upregulation coupled with an inability to block Atm-mediated prosurvival responses.
A small number of patients with 17p deletion can have untreated stable CLL for many years, 44 ,45 but 5-8% of patients coming to treatment for the first time will have 17p deletion and the majority of these patients have a poor outcome. For example, in one trial, fludarabine-based therapy induced median overall survival of about 19 months in CLL patients with 17p deletion and 30 months in those who had p53 mutation without 17p deletion, compared with greater than 7-year overall survival for those with neither. There were few complete remissions in patients with p53 abnormalities. 46 The role of Notch signaling in CLL pathobiology An oncogenic role for Notch signaling is well established in T-acute lymphoblastic leukemia (T-ALL). 29 More than half of the T-ALLs harbor Notch 1 mutations, which result in aberrant activation of this signaling pathway. 47 Targeted expression of the active form of Notch 1 to immature T cells in a zebrafish transgenic model resulted in the development of T-cell leukemias. 48 The presence of Notch mutations are counterintuitively predictive of good initial therapeutic responses, although not of outcome. [49] [50] [51] Therapeutic strategies that combine inhibition of Notch processing by g-secretase inhibitors ( Figure 2 ) with glucocorticoids may be of value in the treatment of T-ALL. 52 Although no Notch mutations have been reported in CLL, emerging data suggest an antiapoptotic role for aberrant Notch activity in this malignancy as well. 53, 54 Unlike normal B cells, CLL cells express both Notch 1 and 2, and their ligands Jagged 1 and 2. Coexpression of the Notch receptors and their ligands results in constitutive Notch signaling. 55 Stimulation by a soluble Jagged 1 ligand results in increased apoptosis resistance, apparently mediated by increased expression of NF-kB and its targets, cellular inhibitors of apoptotic protease 2 and X-linked cellular inhibitors of apoptotic protease. Treatment of CLL cells p53 and Notch in chronic lymphocytic leukemia RG Wickremasinghe et al with a g-secretase inhibitor decreased expression of these proteins and also augmented apoptosis. 55 Taken together, these data suggest that constitutive Notch signaling contributes significantly to the cell-intrinsic apoptosis resistance of CLL cells, mediated at least, in part, by augmented NF-kB target gene expression.
Therapeutic strategies targeting the p53 pathway

Non-genotoxic agents that upregulate p53
Nutlin 3a is a small molecule that blocks the p53-Mdm2 interaction by binding the p53-binding pocket of Mdm2. This compound stabilizes p53 by inhibiting the continuous ubiquitination of p53 by Mdm2 and its consequent degradation. 56 Low micromolar concentrations of nutlin were toxic toward CLL cells in vitro, [57] [58] [59] with minimal toxicity toward normal B lymphocytes or bone marrow hematopoietic progenitors. 59 Apoptotic cell killing was preceded by upregulation of p53 and p53 target genes. 57, 58 Nutlin 3a synergized with chlorambucil or fludarabine. [57] [58] [59] CLL cells with p53 mutations were, as expected, resistant to nutlin 3a, 57, 58 but cells that were resistant to conventional drugs because of low Atm 57, 58 or elevated Mdm2 levels 57 were nevertheless killed by this agent. A simple in vitro test based on comparing p53 upregulation and p53-dependent gene expression in CLL cells treated with the genotoxic agent etoposide and with nutlin readily distinguishes between patients with an intact p53 system, with dysfunctional p53 or dysfunctional ATM, respectively. 60 This test may be of value in selecting patients resistant to cytotoxic drugs by virtue of Atm dysfunction, and who may therefore benefit from nutlin treatment. However, a potential pitfall in the clinical use of nutlin is that treatment with this agent may encourage the selection and expansion of p53-mutant clones, which would be difficult to eliminate by existing therapeutic agents. 61 
Agents that restore function of mutant p53
Restoration of p53 expression by genetic manipulation in a mouse model of lymphoma resulted in tumor apoptosis and regression, with minimal effects on normal tissues. 62 These observations support the concept that tumor cells may provide an environment that permits more sustained p53 function than do normal cells, and underpin the notion that non-genotoxic pharmacological agents that restore p53 function in tumors may be of particular value in securing selective ablation of tumor cells with acceptable collateral toxicity. 63 The small molecule PRIMA-1 stabilizes the conformation of p53 molecules that are inactive as transcription factors due to mutations in the DNA-binding domain. This agent may be potentially useful in the treatment of patients with mutant p53. PRIMA-1 was shown to be toxic toward CLL isolates in vitro. 64 However, detailed mechanistic studies demonstrating that this compound is able to restore an active p53 conformation, resulting in p53-dependent upregulation of proapoptotic genes in CLL cells with mutant p53, have not yet been carried out and will be an essential prerequisite to its possible clinical application.
Therapeutic strategies for CLL patients with a dysfunctional p53 pathway
Loss of genes encoding p53 or its upstream activator Atm identifies a particularly poor prognosis subset of patients, 39, 40 resulting in part from the dependence of conventional cytotoxic agents on the p53 pathway. Clinical trial evidence to date indicates that patients with genetic abnormalities impacting on the p53 pathway need treatment with agents that can act independently of this pathway. It is therefore relevant that the apoptosis-inducing actions of the NF-kB inhibitor parthenolide, 65 roscovitine, 66 flavopiridol, 67 the heat-shock protein 70 inhibitor 2-phenylacetylenesulfonamide 68 and the heat-shock protein 90 inhibitor geldanamycin 69 on CLL cells are independent of p53 status. LC-1, a parthenolide derivative with improved pharmacodynamic properties, is currently in clinical trials (C Pepper, University of Cardiff, personal communication).
ABT 737, a 'BH3-mimetic' drug designed to neutralize the antiapoptotic function of Bcl-2 and related proteins, induces apoptosis of CLL cells at low nanomolar concentrations, [70] [71] [72] [73] and also synergizes with a range of conventional cytotoxic agents 72 and with proteasome inhibitors. 73 It is likely that this drug and its derivatives will bypass p53 and therefore retain toxicity toward p53 dysfunctional CLL cells.
There is as yet no evidence from clinical trials that either anti-CD20 (rituximab) or anti-CD23 (ofatumumab), when used alone or in combination with conventional chemotherapy, significantly improves the outcome for p53 dysfunctional patients. The anti-CD52 antibody, alemtuzumab, induced short-lived remissions independently of p53 status in both de novo and relapsed/fludarabine-refractory patients, but numbers of patients studied with p53 abnormalities are small and there were few complete remissions. 74, 75 Responses were seen in 5 of 12 patients with 17p deletion treated with flavopiridol, a cyclin-dependent kinase inhibitor, which is also p53-independent. 76 Treatment of CLL patients with lenalidomide resulted in upregulation of cell-surface CD154 and generation of antibodies to cell-surface Ror1 protein tyrosine kinase. 77 These observations suggested that lenalidomide's mode of action may be partly dependent on reversing the immune dysfunction characteristic of CLL cells. This immunologically based mechanism is probably at least partially independent of functional p53. Reports of efficacy are available so far only for relapsed or refractory patients, and combined for 17p and 11q abnormalities so far. In those, the overall response rate is an encouraging 30-40% with some complete remissions, although progression-free survival is short. 78, 79 There are ongoing trials of several p53-independent agents, some in patients who have had no previous treatment and some in combination regimes. There is a need to ensure transparency in reporting the results on trials on patients with p53 abnormalities and, as numbers are small, there is a further need to pool data on their responses where possible.
Inhibitors of p53-mediated transcription as potential therapeutic agents in CLL
A recent study by Steele et al. 26 has introduced a novel twist to elucidating the role of p53 in CLL apoptosis. They observed that the bulk of the p53 induced following treatment of CLL cells with chlorambucil, fludarabine or nutlin 3a was preferentially associated with a fraction enriched in mitochondria, with only a small proportion located in the nucleus. A direct association of p53 with mitochondria-localized Bcl-2 was also demonstrated by coimmunoprecipitation. Surprisingly, pifithrin-a (PFT-a), a small molecule that selectively inhibits p53-mediated transcriptional activation, augmented rather than suppressed apoptosis induction by each agent. 26 Puma protein was constitutively expressed by CLL cells, with only a modest upregulation following p53 induction. This modest induction was prevented by PFT-a, demonstrating that the inhibitor was indeed effective in blocking p53-mediated transcription in CLL cells. These data 26 are incompatible with the conventional model ( Figure 3, model A) , which predicts that p53 induces apoptosis exclusively via transcriptional upregulation of proapoptotic proteins. The observations are, however, compatible with model B (Figure 3) . The key features of this model are the overall consequence of p53 elevation in CLL cells is the induction of apoptosis, which occurs predominantly via the non-transcriptional mechanism (arrow 1). The transcriptional induction of proapoptotic proteins may make a modest contribution to apoptosis induction (arrow 2). However, the transcriptional induction of prosurvival proteins (arrow 3) represents the dominant feature of the transcriptional response and serves to limit induction of apoptosis via the non-transcriptional mechanism (arrow 1) and the transcriptional upregulation of proapoptotic proteins (arrow 2). A key prediction of this model is that drugs that block p53-mediated transcription of antiapoptotic proteins (arrow 3) may be exploited to augment the killing of CLL cells with wild-type p53 because the transcriptional contribution to overall apoptosis induction (arrow 2) is small relative to the contribution by the non-transcriptional apoptotic pathway (arrow 1).
The ability of PFT-a to enhance cytotoxic actions of nutlin 3 has also been shown in the ML-1 myeloid leukemia cell line. 80 The cytotoxicity of temozolomide on glioblastoma cell lines with wild-type p53 expression was also enhanced by the PFT-a derivative cyclic PFT-a-p-nitro. 81 This inhibitor also enhanced the antitumor actions of temozolomide on intracranial xenografts of the same cell lines. In contrast, the p53 inhibitor failed to augment killing of p53-null cell lines either in vitro or in vivo, clearly indicating that this pharmacological action of the p53 inhibitor was strictly dependent on the presence of functional p53. 81 This study suggests that the potential utility of p53 transcription inhibitors in enhancing cytotoxic killing may extend to at least some solid tumors and also establishes the important point that combinations of PFT-a and cytotoxic agents can be selectively toxic to cancer cells with acceptable collateral toxicity. We propose that the contributions of the different transcriptional and non-transcriptional pathways of p53-mediated apoptosis regulation are of variable importance in different cell types, and that models A and B (Figure 3 ) represent extremes of diverse mechanisms occurring in different cell types, with the model shown in Figure 3b representing most closely the responses to p53 in CLL cells. In a wide range of cell types, p53-mediated apoptosis is transcription-dependent, in a manner compatible with model A (Figure 3) . Accordingly, PFT-a has been shown to exert antiapoptotic actions in numerous studies both in vitro and in vivo (see references 15-28 cited by Steele et al.
28
). It is therefore plausible that combined treatment with PFT-a (or derivatives thereof) and a p53-elevating cytotoxic agent may result in a useful therapeutic window in the treatment of CLL and of other tumors whose response to p53 elevation conform with model B.
Notch 1 as a potential antiapoptotic p53 target
An intriguing link between p53 and the Notch 1 pathway has been revealed in a study by Secchiero et al. 27 Treatment of primary CLL cells with nutlin 3 resulted in elevation of both p53 and Notch 1. Furthermore, g-secretase inhibitors, which block the generation of the active Notch proteins (Figure 2 ), augmented the cytotoxicity of nutlin 3, compatible with the interpretation that induction of Notch 1 expression by p53 initiated an antiapoptotic feedback mechanism that limited the cytotoxic actions of nutlin 3. The p53 dependence of nutlin-induced Notch 1 expression was demonstrated by the observation that Notch 1 elevation occurred in p53 wild-type myeloid and lymphoid leukemic cell lines but not in lines lacking a functional p53 gene. 27 Furthermore, silencing of p53 expression by transfection of small interfering RNA abrogated induction of Notch 1 by nutlin. Silencing of Notch 1 by small interfering RNA enhanced the cytotoxic actions of nutlin 3, elegantly demonstrating the antiapoptotic role of Notch 1 induction.
These studies therefore show that Notch 1 is a key antiapoptotic target of p53 in both lymphoid and myeloid leukemia cells, and that blockade of Notch induction by g-secretase inhibitors or by antisense approaches may therefore be of therapeutic value in the treatment of CLL by p53-elevating agents including nutlin 3. The severe gastrointestinal toxicity of g-secretase inhibitors may limit their therapeutic utility. However, administration of the g-secretase inhibitor MRK-003 resulted in antileukemic activity in a mouse model of T-ALL in the absence of significant toxicity. 82 Coadministration with glucocorticoids, which limit the gastrointestinal toxicity of g-secretase inhibitors, has also proven effective in a T-ALL model. 83 Although Notch 1 is a candidate mediator of p53's antiapoptotic role, additional targets cannot be ruled out at present. For example, p21 CIP1 can block apoptosis in some cellular contexts. 84 Steele et al. 26 have shown that p21 CIP1 is strikingly upregulated following treatment of CLL cells with p53-elevating agents and that this upregulation was blocked by PFT-a.
Summary and perspectives
This review has summarized the mechanisms involved in the activation of the p53 and Notch signaling pathways and their roles in the modulation of apoptosis. Studies have also been summarized that have identified potential new therapeutic strategies for CLL, which are based on the growing understanding of the functions of these pathways in CLL cells. We have emphasized a novel model suggesting that p53's transcriptional function results predominantly in a feedback antiapoptotic response, whereas the major route by which this protein induces apoptosis involved a direct biochemical action at the mitochondrial outer membrane. Unlike the conventional model of p53-induced apoptosis, the novel model predicts that pharmacological inhibition of p53's transcriptional function will augment rather than suppress apoptosis induction by agents that elevate cellular p53 levels. A growing body of experimental data show that the new model may apply to myeloid leukemias and to at least some solid tumors in addition to CLL. We anticipate that studies of the type summarized here will be extended to other malignancies and will provide an impetus for the development of p53 inhibitors with improved pharmacological characteristics.
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